Examining the link between pancreatic steatosis and pancreatic cysts and cancer
Official title: The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study
Run by Carol Davila University of Medicine and Pharmacy · NCT06867172 · Data updated 2026-11-12
This study is trying to see if having fat in the pancreas is more common in people with pancreatic cysts that could turn into cancer and those with pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Carol Davila University of Medicine and Pharmacy Academic / other |
| Locations | 1 site (Bucharest, Sector 1) |
| Status | Recruiting |
| Started | January 1, 2019 |
| Main results expected | March 31, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | March 10, 2025 |
| Trial ID | NCT06867172 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 or older with at least one pancreatic cystic lesion or those diagnosed with pancreatic adenocarcinoma.
✕Probably not a fit
Patients with significant alcohol consumption or those with contraindications for endoscopy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the prevalence of pancreatic steatosis in patients with pancreatic cystic neoplasms and pancreatic adenocarcinoma. It will utilize imaging techniques such as computerized tomography (CT) and endosonography (EUS) to evaluate the presence of steatosis in these conditions. The primary goal is to determine if pancreatic steatosis is more common in cystic lesions that have a risk of cancer development. Additionally, the study will explore the prevalence of steatosis in patients diagnosed with pancreatic adenocarcinoma.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the relationship between pancreatic steatosis and cancer risk, potentially leading to improved diagnostic and treatment strategies.
How similar studies have gone: While the relationship between pancreatic steatosis and pancreatic cancer is emerging, this specific investigation into cystic neoplasms is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam). Exclusion Criteria: * No evidence of written informed consent * Patients with contraindications for endoscopy due to comorbidities * Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary) * Acute pancreatitis at baseline imaging * Pancreatic surgery at baseline imaging in our department * Splenectomy * Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Where it's running
-
Prof Dr Agrippa Ionescu; Clinical Emergency Hospital
Bucharest, Sector 1, Romania Recruiting
Study contacts
- Study coordinator: Catalina Vladut, MD PhD
- Email: drcatalinavladut@gmail.com
- Phone: +40751015445
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using technology to improve care for pancreatic cancer patients
This study is trying to see if sharing patient data among hospitals can help improve care and outcomes for people with pancreatic cancer.
-
Understanding pancreatic fat and cyst features in patients
This study is trying to see if measuring fat in the pancreas and liver can help find early signs of dangerous pancreatic cysts in patients who might be at risk for pancreatic cancer.
-
Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer
This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.
-
Blood and cyst fluid analysis from patients undergoing pancreatic cyst surgery
Researchers will collect blood and cyst fluid from adults having pancreatic cysts surgically removed to test for DNA, RNA, and proteins.
-
XYA02 in advanced solid tumors
This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.
-
Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer
This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.